Pediatric blood & cancer

publication venue for

Pleuroparenchymal fibroelastosis as a late complication of childhood cancer therapy: A case series. 2024
Does anti-HPA-1a affect birthweight in fetal and neonatal alloimmune thrombocytopenia? 2024
Longitudinal assessment of Leydig cell function in male survivors of childhood cancer. 2023
A quality improvement initiative standardizing premedication for blood product transfusions. 2023
Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. 2023
Position paper: The time for cooperative group study of ropeginterferon alfa-2b in young patients with myeloproliferative neoplasms is now. 2023
Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma. 2023
Fertility assessment and treatment in adolescent and young adult cancer survivors. 2023
Slipped capital femoral epiphyses: A major on-target adverse event associated with FGFR tyrosine kinase inhibitors in pediatric patients. 2023
v-SYMPHONY career development series: A collaboration to enhance professional awareness for pediatric hematology oncology trainees. 2022
Imaging of pediatric hematopoietic stem cell transplant recipients: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.. 70 Suppl 4. 2022
Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastoma. 2022
Effects of COVID-19 vaccination on platelet counts and bleeding in children, adolescents, and young adults with immune thrombocytopenia. 2022
Imaging of pediatric thyroid tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.. 70 Suppl 4. 2022
Lack of complete response pretransplant is not associated with inferior overall survival for stage 4a metastatic retinoblastoma. 2022
Chemotherapy-induced thrombocytopenia in pediatric oncology: Scope of the problem and opportunities for intervention. 2022
Second cancer risk in childhood cancer survivors treated with intensity-modulated radiation therapy: An updated analysis of more than 10 years of follow-up.. 69. 2022
Recommended scoring approach for the pediatric patient-reported outcomes version of the Common Terminology Criteria for Adverse Events. 2021
Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.. 69. 2021
KMT2A-MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8-year follow-up.. 69. 2021
Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma.. 68. 2021
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force.. 68. 2021
Pyruvate kinase deficiency in children.. 68. 2021
COVID-19 has changed the way we think about training future pediatric hematologists/oncologists.. 68. 2021
Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody.. 68. 2021
General cancer screening practices among adult survivors of retinoblastoma: Results from the Retinoblastoma Survivor Study.. 68. 2021
Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.. 68. 2020
COVID-19 in pediatric survivors of childhood cancer and hematopoietic cell transplantation from a single center in New York City.. 68. 2020
Retinoblastoma management in 13q deletion syndrome patients using super-selective chemotherapies and other cancer-directed interventions.. 68. 2020
Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastoma.. 67. 2020
Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience.. 67. 2020
Whole-body magnetic resonance imaging as surveillance for subsequent malignancies in preadolescent, adolescent, and young adult survivors of germline retinoblastoma: An update.. 67. 2020
Expanding construct validity of established and new PROMIS Pediatric measures for children and adolescents receiving cancer treatment.. 67. 2020
Treatment of pediatric high-grade central nervous system tumors with high-dose methotrexate in combination with multiagent chemotherapy: A single-institution experience.. 67. 2019
Assessment of pulmonary outcomes, exercise capacity, and longitudinal changes in lung function in pediatric survivors of high-risk neuroblastoma.. 66. 2019
Utilization of integrative medicine differs by age among pediatric oncology patients.. 66. 2019
Content review of pediatric ethics consultations at a cancer center.. 66. 2019
Ethical considerations of using a single minor donor for three bone marrow harvests for three HLA-matched siblings with primary immunodeficiency.. 66. 2019
Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis.. 66. 2018
Insulin and glucose homeostasis in childhood cancer survivors treated with abdominal radiation: A pilot study.. 65. 2018
Dose-escalation is needed for gross disease in high-risk neuroblastoma.. 65. 2018
Nutritional risk factors predict severe acute graft-versus-host disease and early mortality in pediatric allogeneic hematopoietic stem cell transplantation.. 65. 2017
A phase II study of radioimmunotherapy with intraventricular ¹³¹ I-3F8 for medulloblastoma.. 65. 2017
High birth prevalence of sickle cell disease in Northwestern Tanzania.. 65. 2017
Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.. 65. 2017
Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience.. 64. 2017
Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.. 64. 2017
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.. 64. 2016
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.. 64. 2016
Hepatocellular adenoma among adult survivors of childhood and young adult cancer.. 64. 2016
Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.. 64. 2016
A single-center experience with undifferentiated embryonal sarcoma of the liver.. 63. 2016
Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults.. 63. 2016
Late Toxicities of Intensity-Modulated Radiation Therapy for Head and Neck Rhabdomyosarcoma.. 63. 2016
Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee.. 63. 2016
Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.. 63. 2016
Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms.. 63. 2016
Intensity-Modulated Radiation Therapy With Dose Painting: A Brain-Sparing Technique for Intracranial Germ Cell Tumors.. 63. 2015
Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.. 63. 2015
Identification of Discrete Prognostic Groups in Ewing Sarcoma.. 63. 2015
Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma.. 62. 2015
Extraneural metastases of medulloblastoma: desmoplastic variants may have prolonged survival.. 62. 2014
Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).. 62. 2014
Ovarian function in survivors of childhood medulloblastoma: Impact of reduced dose craniospinal irradiation and high-dose chemotherapy with autologous stem cell rescue.. 62. 2014
Radiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma.. 62. 2014
Pubertal development and primary ovarian insufficiency in female survivors of embryonal brain tumors following risk-adapted craniospinal irradiation and adjuvant chemotherapy.. 62. 2014
Second cancer risk in childhood cancer survivors treated with intensity-modulated radiation therapy (IMRT).. 62. 2014
Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.. 62. 2014
Transfusion related iron overload in pediatric oncology patients treated at a tertiary care centre and treatment with chelation therapy.. 61. 2014
Combined umbilical cord blood and bone marrow from HLA-identical sibling donors for hematopoietic stem cell transplantation in children with hemoglobinopathies.. 61. 2014
Favorable outcomes after whole abdominopelvic radiation therapy for pediatric and young adult sarcoma.. 61. 2014
Safety profile of long-term intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignancies.. 61. 2014
Testicular tissue cryopreservation in prepubertal male children: an analysis of parental decision-making.. 61. 2014
HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study.. 61. 2014
Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia.. 61. 2014
Neuroblastoma and pediatric delirium: a case series.. 61. 2013
Marker (+) CNS germ cell tumors in remission: are surveillance MRI scans necessary?. 61. 2013
Genome-wide analysis of DNA copy number alterations and loss of heterozygosity in intracranial germ cell tumors.. 61. 2013
Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: a pilot study.. 61. 2013
Pulmonary outcomes in survivors of childhood central nervous system malignancies: a report from the Childhood Cancer Survivor Study.. 61. 2013
Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.. 61. 2013
Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.. 61. 2013
Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.. 60. 2013
High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: a report from the Children's Oncology Group.. 60. 2013
The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study.. 61. 2013
Intensity-modulated radiation therapy with dose-painting for pediatric sarcomas with pulmonary metastases.. 60. 2013
The palatability and tolerability of deferasirox taken with different beverages or foods.. 60. 2013
Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea.. 60. 2013
Reduced cardiorespiratory fitness in adult survivors of childhood acute lymphoblastic leukemia.. 60. 2013
Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastoma.. 60. 2013
Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung.. 60. 2012
Prevalence of vitamin D insufficiency in survivors of childhood cancer.. 60. 2012
Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease.. 60. 2012
Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience.. 60. 2012
Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.. 59. 2012
Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: a childhood cancer survivor study report.. 60. 2012
Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment.. 59. 2012
Paroxysmal nocturnal hemoglobinuria in pediatric patients.. 59. 2011
Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP).. 58. 2011
Impact of PET-CT on involved field radiotherapy design for pediatric Hodgkin lymphoma.. 58. 2011
Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: a report from the Children's Oncology Group.. 57. 2011
Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma.. 57. 2011
Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma.. 58. 2011
Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study.. 57. 2011
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.. 56. 2011
Auditory complications in childhood cancer survivors: a report from the childhood cancer survivor study.. 57. 2011
Characteristics and outcome of radiation and chemotherapy-related mucoepidermoid carcinoma of the salivary glands.. 57. 2011
Adipokines, body fatness, and insulin resistance among survivors of childhood leukemia.. 58. 2011
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.. 55. 2010
Education and employment status of children and adults with thalassemia in North America.. 55. 2010
Height impairment after lower dose cranial irradiation in children with acute lymphoblastic leukemia.. 56. 2010
High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma.. 55. 2010
Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma.. 55. 2010
Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma.. 55. 2010
Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.. 54. 2010
Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system.. 54. 2010
Trilateral retinoblastoma: potentially curable with intensive chemotherapy.. 54. 2010
Ocular late effects in childhood and adolescent cancer survivors: a report from the childhood cancer survivor study.. 54. 2010
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.. 53. 2009
Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.. 53. 2009
Familial retinoblastoma in developing countries.. 53. 2009
Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.. 53. 2009
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma.. 53. 2009
One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.. 52. 2009
Vancomycin-resistant enterococcus in pediatric oncology patients: An analysis of potential consequences of colonization and infection.. 52. 2009
Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.. 51. 2008
The prognostic value of tumor markers in newly diagnosed patients with primary central nervous system germ cell tumors.. 51. 2008
A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation.. 50. 2008
Brain-sparing radiotherapy for neuroblastoma skull metastases.. 50. 2008
Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols.. 50. 2008
The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.. 50. 2008
Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy.. 50. 2008
Timing of menarche among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.. 50. 2008
Brainstem primitive neuroectodermal tumors (bstPNET): results of treatment with intensive induction chemotherapy followed by consolidative chemotherapy with autologous hematopoietic cell rescue.. 50. 2008
Impairments in antifolate transport are common in retinoblastoma tumor samples.. 50. 2008
World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group.. 50. 2008
Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience.. 50. 2008
Neurotrophin receptor expression in human primary retinoblastomas and retinoblastoma cell lines.. 50. 2008
Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine.. 50. 2008
Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group.. 49. 2007
A phase II trial of carboplatin for intraocular retinoblastoma.. 49. 2007
Loss of antibody titers and effectiveness of revaccination in post-chemotherapy pediatric sarcoma patients.. 49. 2007
A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies.. 49. 2007
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.. 49. 2007
Factors associated with health-related quality of life in pediatric cancer survivors.. 49. 2007
Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma.. 49. 2007
Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma.. 49. 2007
Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.. 49. 2007
High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.. 48. 2007
A proposal for an international retinoblastoma staging system.. 47. 2006
Pediatric surface osteosarcoma: clinical, pathologic, and radiologic features.. 47. 2006
More aggressive bone marrow screening in retinoblastoma patients is not indicated: the memorial Sloan-Kettering cancer center experience.. 46. 2006
Prognostic value of MYCN and ID2 overexpression in neuroblastoma.. 45. 2005
Long-term complications in survivors of advanced stage neuroblastoma.. 45. 2005
Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia.. 45. 2005
Intensive cisplatin and cyclophosphamide-based chemotherapy without radiotherapy for intracranial germinomas: failure of a primary chemotherapy approach.. 43. 2004
Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia.. 42. 2004
Fertility of long-term male survivors of acute lymphoblastic leukemia diagnosed during childhood.. 42. 2004
High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors.. 42. 2004
The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience.. 42. 2004
Polycythemia vera in a 2-year-old child with a JAK2 exon 12 deletion.. 68. 2021
An unusual case of opsoclonus-myoclonus-ataxia syndrome associated neuroblastoma: High-risk disease requiring immunotherapy.. 67. 2020
SARS-CoV-2 infection in two pediatric patients with immune cytopenias: A single institution experience during the pandemic.. 67. 2020
Late complications of mixed chimerism following allogeneic bone marrow transplantation for thalassemia major.. 62. 2015
Antibody induced pain in children: An opportunity to study pain mechanism, IgG design and analgesics.. 62. 2014
Health promotion for adolescent leukemia survivors. 2012
Induction for high-risk neuroblastoma. 2007
Treatment reduction for neuroblastoma. 2004
Delirium in a patient with trisomy 21 undergoing chemotherapy for high-risk acute lymphoblastic leukemia. 2022
De novo antiphospholipid antibody syndrome in two infants. 2022
COVID-19 disease in New York City pediatric hematology and oncology patients. 2020
Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy? 2016
Lack of early bevacizumab-related skeletal radiographic changes in children with neuroblastoma. 2009
Pediatric glioblastoma in the setting of constitutional mismatch-repair deficiency treated with upfront lomustine and nivolumab. 2023
Why do young people get cancer? 2020
Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. 2017
Imaging and management of fetuses and neonates with alloimmune thrombocytopenia. 2017
Kaposi Sarcoma of Childhood: Inborn or Acquired Immunodeficiency to Oncogenic HHV-8. 2015
Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. 2015
ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma. 2014
Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors. 2013
Strategies to manage retinoblastoma in developing countries. 2010
Advances in the clinical management of high-risk Wilms tumors. 2023
Pediatric refractory immune thrombocytopenia: A systematic review. 2022
The tumor microenvironment and immune targeting therapy in pediatric renal tumors. 2022
Sickle cell in Latin America and the United States [corrected]. 2015

VIVO Weill Cornell Medical College

Pediatric blood & cancer Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)